CYP19A1 and breast carcinoma: Aromatase inhibitors (AIs) and tamoxifen, a selective estrogen receptor modulator, are two effective hormonal therapies commonly used in the treatment of breast cancer, which have been associated with increased risk of AF [2, 3].